Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.36 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.36 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | KHK | P50053 | 2/20 | 0.35 |
| ▸ | GALR2 | O43603 | 1/20 | 0.35 |
| ▸ | GALR1 | P47211 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878041 | 0.95 | MALT1 (0.44) | MALT1DYRK1AMAP3K12TRPV1CHRM4 | |
| SCHEMBL3875754 | 0.93 | TRPV1 (0.37) | MALT1DYRK1AMAP3K12TRPV1CHRM4 | |
| SCHEMBL3877937 | 0.92 | DYRK1A (0.38) | DYRK1AKCNH2MAP3K12TRPV1CHRM4 | |
| SCHEMBL3877824 | 0.91 | MALT1 (0.41) | MALT1DYRK1AMAP3K12CHRM4KHK | |
| SCHEMBL3879378 | 0.91 | TRPV1 (0.47) | TRPV1GALR2GALR1 | |
| SCHEMBL3878207 | 0.90 | GRM5 (0.41) | DYRK1AMAP3K12TRPV1KHKGALR2 | |
| SCHEMBL13761444 | 0.90 | MALT1 (0.47) | MALT1 | |
| SCHEMBL3887559 | 0.89 | SYK (0.43) | DYRK1AMAP3K12TRPV1CHRM4KHK | |
| SCHEMBL3876175 | 0.88 | TRPV1 (0.48) | TRPV1CHRM4KHKGALR2GALR1 | |
| SCHEMBL3879062 | 0.88 | TRPV1 (0.43) | MALT1DYRK1ATRPV1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | MALT1 1393/4885DYRK1A 2887/4885CHI3L1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.